HIGHLIGHTS
- who: Hsiang-Fong Kao from the Department of Oncology, National Taiwan University Hospital, No7, Chung have published the research: Short-course pembrolizumab and continuous afatinib therapy for recurrent or metastatic head and neck squamous cell carcinoma: a real-world data analysis, in the Journal: (JOURNAL) of June/30,/2022
- what: After obtaining positive results in a phase II trial , the authors focused on patients taking a short course of pembrolizumab with continuous afatinib in this realworld data set. The Cox proportional hazards regression analysis in the study showed that a lower dose of pembrolizumab (2 . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.